A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenstrom Macroglobulinemia Biology
Roccaro A, Sacco A, Jimenez C et al.
Key Points:
Mutation status of chemokine receptor type 4 (CXCR4) characterized
28% of patient with WM have C1013GCXCR4 mutation.
Implications:
- C1013GCXCR4 acts as activating mutation in WM and can be attacked by novel antibody MDX936564/1338 with anti-WM activity in vitro and in vivo.
View the original abstract on the ASH website.
